Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2021-06-14 Regulatory Filings
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically announces that BioCardia, Inc. will join the Russell Microcap Index following the annual reconstitution. There is no detailed financial data, management discussion, or comprehensive report content. The document includes a press release as an exhibit but does not contain the report itself. The length is 3211 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-06-14 English
FORM 4
Director's Dealing
2021-06-11 English
FORM 4
Director's Dealing
2021-06-11 English
FORM 4
Director's Dealing
2021-06-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2021, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2021. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length is 3359 characters, which is relatively short and consistent with an announcement rather than a full earnings release or quarterly report. The document explicitly states it is a 'Current Report' and includes a press release as an exhibit. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full financial results or detailed analysis itself. It is not an Earnings Release (ER) because it does not contain key highlights directly but references a press release. It is not an Interim/Quarterly Report (IR) because it lacks substantive financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-05-13 English
FORM 10-Q
Interim / Quarterly Report Q1 2021
2021-05-13 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.